You are here

Clementia Pharmaceuticals

Ipsen doubles down on rare bone disease

Ipsen doubles down on rare bone disease

EP Vantage

Blueprint Medicines

Clementia Pharmaceuticals

Flag link:

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Endpoints

Clementia Pharmaceuticals

Flag link:

With clear FDA path, Clementia raises $70.2M

With clear FDA path, Clementia raises $70.2M

BioCentury

Clementia Pharmaceuticals

fibrodysplasia ossificans progressiva

Flag link:

Clementia jumps on NDA plans for unmet rare bone disease

Clementia jumps on NDA plans for unmet rare bone disease

BioCentury

Clementia Pharmaceuticals

Flag link: